title: Human immunodeficiency virus: anesthetic and obstetric considerations.
abstract: The pandemic of acquired immune deficiency syndrome (AIDS) is on the threshold of its third decade of existence. The World Health Organization-United Nations statistics show that human immunodeficiency virus (HIV)/AIDS pandemia is set to get much worse. Women of reproductive age are the fastest growing population with HIV. Common signs and symptoms have become more moderate or subclinical, and new clinical presentations have emerged. It is quite apparent that HIV-disease affects multiple organ systems. Advances have been made in elucidating the pathogenesis of HIV. In addition, the molecular technique of viral load determination and the CD + 4 T-lymphocyte count enable evaluation of the disease, its prognosis, and its response to therapy. There is limited specific information concerning the overall risk of anesthesia and surgery of HIV/AIDS patients. However, as far as can be determined, surgical interventions do not increase the postoperative risk for complications or death and should therefore not be withheld. There is also little evidence to suggest that HIV or antiretroviral drugs increase the rate of pregnancy complications or that pregnancy may alter the course of HIV infection. General anesthesia is considered safe, but drug interactions and their impact on various organ systems should be considered preoperatively. Regional anesthesia is often the technique of choice. Yet, one must take into consideration the presence of neuropathies, local infection, or blood clotting abnormalities. It should be emphasized that all practicing anesthesiologists should be familiar with the disease and should use prenatal anesthesia consultations and a team approach to assure optimal treatment for HIV patients.
authors.affiliation: *Obstetric Anesthesia Unit, the †Department of Obstetrics and Gynecology, the ‡Ambulatory Surgical Unit, §Delivery Ward, ∥Department of Anesthesia, The Edith Wolfson Medical Center, Holon (Israel), Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Shmuel
authors.initials: S
authors.lastname: Evron
authors.forename: Marek
authors.initials: M
authors.lastname: Glezerman
authors.forename: Ethan
authors.initials: E
authors.lastname: Harow
authors.forename: Oscar
authors.initials: O
authors.lastname: Sadan
authors.forename: Tiberiu
authors.initials: T
authors.lastname: Ezri
mesh_terms: D000328:Adult; D000773:Anesthesia, Obstetrical / Q000009:adverse effects; D000777:Anesthetics / Q000009:adverse effects; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D036861:Delivery, Obstetric; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000503:physiopathology
chemical_list: D000777:Anesthetics; D019380:Anti-HIV Agents